USPTO Examiner ALAWADI SARAH - Art Unit 1619

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17120856PRODUCTDecember 2020May 2024Abandon4101NoNo
16972008LOW GLYCEMIC COMPOSITION AND METHODS OF MAKING AND USING THEREOFDecember 2020May 2024Abandon4101NoNo
17059428MILD COMPOSITION FOR USE IN TOPICAL TREATMENT OF SKIN AND NAIL DISORDERS CAUSED BY VIRUS AND FUNGUSNovember 2020April 2024Abandon4121NoNo
17084514PHARMACEUTICAL OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOFOctober 2020July 2022Allow2110NoNo
17083232PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOFOctober 2020October 2022Allow2300NoNo
17077969COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDOctober 2020January 2025Abandon5180YesNo
17077897OXYGENATED SKIN LOTIONOctober 2020October 2023Abandon3611NoNo
17070365ANTIMICROBIAL COMBINATIONS SYSTEM AND METHODOctober 2020December 2023Abandon3821NoNo
17067676ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEOctober 2020July 2023Abandon3310NoNo
17067259TOPICAL FORMULATIONS COMPRISING STRONTIUM AND METHYLSULFONYLMETHANE (MSM) AND METHODS OF TREATMENTOctober 2020October 2023Allow3631YesNo
17060121Antibacterial and Non-Clumping Liquid SprayOctober 2020January 2023Abandon2720NoNo
17042473ANTIPERSPIRANT PRODUCTSSeptember 2020February 2024Abandon4110NoNo
17033294TREATMENT AND PROPHYLAXIS OF RADIATION DERMATITISSeptember 2020August 2023Allow3510YesNo
17040825SOLUTIONS COMPRISING OZONIZED OILSeptember 2020November 2023Abandon3701NoNo
16977048COMPOSITE PARTICLESAugust 2020October 2024Abandon4911NoNo
17001726Slow Release Calcium CompositionAugust 2020July 2021Allow1111YesNo
16991397Praziquantel FormulationsAugust 2020March 2022Abandon1931NoNo
16988387COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDAugust 2020February 2025Abandon5450NoNo
16941400COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDJuly 2020September 2020Allow200YesNo
16941414COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDJuly 2020September 2020Allow200YesNo
16929140NUTRITIONAL SUPPLEMENT FOR GROWTH ENHANCEMENTJuly 2020February 2021Allow710NoNo
16927613PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COVID-19July 2020July 2023Abandon3610NoNo
16916713COMPOSITION AND PROCESS FOR REMOVING MILDEW AND FUNGAL GROWTHJune 2020July 2021Abandon1220NoNo
16912734METHOD FOR DISINFECTION OF ITEMS AND SPACESJune 2020May 2022Allow2240YesNo
16772788FILM FORMULATION COMPRISING VARDENAFIL, METHOD FOR ITS PREPARATION, AND USE THEREOFJune 2020August 2022Abandon2611NoNo
16772481AN ANTIMICROBIAL COMPOSITIONJune 2020November 2023Abandon4110NoNo
16900507COMPOSITIONS AND METHODS FOR TREATING WOUNDSJune 2020October 2022Abandon2811NoNo
16771779PHARMACEUTICAL COMPOSITION COMPRISING A COLLOIDAL DISPERSION AND A THERAPEUTIC AGENT AND METHODS AND USES THEREOFJune 2020July 2024Abandon4911NoNo
16898990MATERIAL TO FORM A HYDROGELJune 2020March 2021Allow900NoNo
16769843AN ANTIMICROBIAL COMPOSITIONJune 2020May 2024Abandon4751NoNo
16892382Antibacterial and Non-Clumping Liquid SprayJune 2020June 2023Abandon3610NoNo
16769682FAST-ACTING BIOCIDAL CLEANSING COMPOSITIONJune 2020April 2025Abandon5841NoNo
16892421COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDJune 2020November 2020Allow510NoNo
15931797Antibacterial and Non-Clumping Liquid SprayMay 2020September 2021Abandon1620NoNo
16872554ANTIBACTERIAL MATERIAL AND ANTIBACTERIAL FILM AND ANTIBACTERIAL MEMBER USING THE SAMEMay 2020October 2023Allow4110YesNo
16869199METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEXMay 2020September 2023Allow4120YesNo
16859609Magic Skin Repair SerumApril 2020July 2023Abandon3901NoNo
16855717TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSApril 2020September 2022Allow2940NoNo
16830539C3-C5 N-Alkyl-Gamma-Butyrolactam-Containing Antimicrobial Compositions and Uses ThereofMarch 2020June 2021Allow1521YesNo
16827940WOUND HEALING TOPICAL FORMULATION AND PREPARATION THEREOFMarch 2020January 2022Abandon2111NoNo
16818488Compositions and Methods for Inhibiting Endospores Using Green Tea PolyphenolsMarch 2020February 2024Abandon4741YesNo
16795779METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURESFebruary 2020April 2023Allow3731YesYes
16745712Antibacterial and Non-Clumping Liquid SprayJanuary 2020January 2023Abandon3630NoNo
16735209COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAINJanuary 2020February 2023Allow3740YesNo
16721872COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERSDecember 2019March 2024Abandon5141YesNo
16621764MICROBICIDAL COMPOSITIONDecember 2019January 2022Abandon2501NoNo
16676325COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUIDNovember 2019March 2020Allow410YesNo
16609839BACTERICIDE COMPOSITIONOctober 2019May 2023Abandon4341YesNo
16665473ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEOctober 2019January 2021Abandon1510NoNo
16497694ANTIBACTERIAL BIOLOGICAL IMPLANTSeptember 2019January 2021Allow1610YesNo
16576301ANTICOAGULATION FLUID COMPRISING CITRATE AND PHOSPHATESeptember 2019April 2021Allow1930YesNo
16495159ODOR CONTROL AGENTSeptember 2019November 2021Abandon2620NoNo
16494789Treatment of herpes simplex symptoms on skin and mucous membrane of mammalsSeptember 2019May 2022Abandon3221NoNo
16492999HAIR CARE COMPOSITIONSeptember 2019September 2021Allow2521YesNo
16567660TOPICAL ANTISEPTIC SYSTEMSeptember 2019December 2021Allow2831YesNo
16483889COMPOSITION COMPRISING IMMEDIATE RELEASE AND EXTENDED RELEASE CAPECITABINEAugust 2019July 2020Abandon1101NoNo
16522259ENHANCED ANTIBIOTIC AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS FOR HUMAN AND VETERINARY USESJuly 2019April 2023Abandon4451YesNo
16515390Slow Release Calcium CompositionJuly 2019January 2021Abandon1821NoNo
16477889STABLE LIQUID COMPOSITION COMPRISING BOTULINUM TOXINJuly 2019September 2021Allow2621NoNo
16476019ORAL DOSAGE FORM FOR ENHANCED SOLUBILIZATION OF A POORLY SOLUBLE ACTIVE AGENT AND METHOD OF PREPARATIONJuly 2019June 2024Allow6061YesNo
16473939ANHYDROUS COMPOSITION COMPRISING A MAGNESIUM SALTJune 2019August 2023Allow5051YesNo
16450159DEODORANT STICKSJune 2019May 2024Abandon5941YesYes
16470890COMPOSITION FOR ALLEVIATING ATOPIC SKIN SYMPTOMS, CONTAINING POLY-GAMMA-GLUTAMIC ACIDJune 2019November 2021Abandon2930NoNo
16444473COMPOSITION AND PROCESS FOR REMOVING MILDEW AND FUNGAL GROWTHJune 2019October 2020Abandon1620YesNo
16440855CONTAINERS THAT CONTAIN ANIONIC CANNABINOID MOLECULES DISSOLVED IN WATERJune 2019March 2020Abandon921NoNo
16440889METHODS OF ADMINISTERING ANIONIC CANNABINOID MOLECULES DISSOLVED IN WATERJune 2019August 2020Allow1421YesNo
16440878METHODS OF PRODUCING ANIONIC CANNABINOID MOLECULES DISSOLVED IN WATERJune 2019September 2019Allow300YesNo
16434959FORMALDEHYDE-FREE PRESERVATIVES FOR HIGHLY SUSCEPTIBLE PRODUCTSJune 2019February 2021Abandon2021NoNo
16428216SPORICIDAL METHODS AND COMPOSITIONSMay 2019September 2022Allow4041YesNo
16462689METHOD AND "IDEPS" COMPOSITION FOR DESTROYING MICROORGANISMS IN A SESSILE STATEMay 2019April 2021Allow2311YesNo
16416689COATING FOR MEDICAL EQUIPMENT AND ENDOSCOPEMay 2019September 2020Abandon1620NoNo
16416369Pharmaceutical Composition of Acetaminophen/IbuprofenMay 2019January 2021Abandon1921NoNo
16462069USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOURMay 2019March 2025Abandon6051NoYes
16415339BOTANICAL FILM-FORMING ACNE COMPOSITIONSMay 2019June 2021Abandon2521NoNo
16411801SHELLAC AND PACLITAXEL COATED CATHETER BALLOONSMay 2019July 2021Allow2621YesNo
16349796MATERIALS AND METHODS FOR THE CONTROL OF NEMATODESMay 2019July 2021Allow2631YesNo
16394289CAROTENOID-CONTAINING COMPOSITIONApril 2019August 2020Abandon1611NoNo
16344739ENGINEERED BIOCOMPATIBLE ANTIBIOTIC PARTICLES AND THEIR USE AGAINST URINARY TRACT INFECTIONApril 2019March 2021Abandon2311NoNo
16380186Biopharma Application Of Micell TechnologyApril 2019July 2021Abandon2721NoNo
16370319SELF-HEALING HYDROGEL AND USE THEREOFMarch 2019January 2022Abandon3441NoNo
16334976ORAL MODIFIED RELEASE FORMULATIONSMarch 2019January 2021Abandon2221NoNo
16292639STERILE INJECTABLE COMPOSITION COMPRISING MELPHALANMarch 2019April 2020Abandon1310NoNo
16280112Chemical Formulations and Their Use in Neutralizing or Eliminating OdorsFebruary 2019June 2021Allow2821YesNo
16281026CONTROLLED DELIVERY SYSTEMFebruary 2019April 2022Abandon3820YesYes
16275739PHARMACEUTICAL MATRIX FORMULATIONS COMPRISING DIMETHYL FUMARATEFebruary 2019October 2022Allow4460NoNo
16266513ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINEFebruary 2019February 2020Abandon1210NoNo
16322819ZINC OXIDE-CONTAINING COMPOSITE PARTICLES, ULTRAVIOLET-SHIELDING COMPOSITION, AND COSMETICFebruary 2019March 2021Abandon2621NoNo
16259541Drug/polymer Composite Materials And Methods Of Making The SameJanuary 2019September 2021Abandon3240NoNo
16256389COMPOSITION FOR PRODUCING HYDROGEN RICH WATER AND OTHER PRODUCTSJanuary 2019January 2022Allow3641YesYes
16256857METHODS AND DRESSINGS FOR SEALING INTERNAL INJURIESJanuary 2019September 2021Abandon3211NoNo
16256565COMPOSITIONS AND METHODS FOR MULTIPURPOSE DISINFECTION AND STERILIZATION SOLUTIONSJanuary 2019April 2021Abandon2730NoNo
16254850PENFLUFEN AS A WOOD PRESERVATIVE AGAINST WOOD-DESTROYING BASIDIOMYCETESJanuary 2019March 2023Allow5040NoYes
16250349HEMOSTATIC MATERIAL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAMEJanuary 2019January 2021Allow2421YesNo
16243842Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active AgentJanuary 2019September 2021Allow3240YesNo
16240249FOAMING CREAM EMULSIONSJanuary 2019November 2024Abandon6071YesYes
16233503TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSDecember 2018January 2020Allow1310NoNo
16229865TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSDecember 2018March 2022Allow3950YesNo
16311944COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDERDecember 2018May 2024Abandon6041YesYes
16227089PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSEDecember 2018May 2020Abandon1710NoNo
16310423A Novel formulation for rapid wound healing and control of infectionDecember 2018January 2024Abandon6001NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALAWADI, SARAH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
57
Examiner Affirmed
51
(89.5%)
Examiner Reversed
6
(10.5%)
Reversal Percentile
23.4%
Lower than average

What This Means

With a 10.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
113
Allowed After Appeal Filing
13
(11.5%)
Not Allowed After Appeal Filing
100
(88.5%)
Filing Benefit Percentile
15.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 11.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALAWADI, SARAH - Prosecution Strategy Guide

Executive Summary

Examiner ALAWADI, SARAH works in Art Unit 1619 and has examined 644 patent applications in our dataset. With an allowance rate of 36.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner ALAWADI, SARAH's allowance rate of 36.5% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALAWADI, SARAH receive 2.79 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALAWADI, SARAH is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +42.8% benefit to allowance rate for applications examined by ALAWADI, SARAH. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.9% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.1% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 45.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 36.0% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 56.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 70.3% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.4% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.